Research Analysts’ Updated EPS Estimates for February 20th (BMRN, CNK, HLF, HR, IMAX, IMUX, LKQ, OMER, RCEL, SWTX)

Research Analysts’ updated eps estimates for Thursday, February 20th:

BioMarin Pharmaceutical (NASDAQ:BMRN) had its outperform rating reiterated by analysts at Wedbush. The firm currently has a $94.00 target price on the stock.

Cinemark (NYSE:CNK) had its outperform rating reaffirmed by analysts at Macquarie. They currently have a $35.00 price target on the stock.

Herbalife (NYSE:HLF) had its neutral rating reaffirmed by analysts at DA Davidson. They currently have a $7.50 price target on the stock.

Healthcare Realty Trust (NYSE:HR) had its outperform rating reiterated by analysts at Wedbush. Wedbush currently has a $16.00 price target on the stock.

IMAX (NYSE:IMAX) had its price target raised by Macquarie from $28.00 to $30.00. They currently have an outperform rating on the stock.

Immunic (NASDAQ:IMUX) had its buy rating reiterated by analysts at D. Boral Capital. The firm currently has a $17.00 price target on the stock.

LKQ (NASDAQ:LKQ) had its outperform rating reiterated by analysts at Barrington Research. They currently have a $60.00 target price on the stock.

Omeros (NASDAQ:OMER) had its buy rating reissued by analysts at D. Boral Capital. The firm currently has a $36.00 price target on the stock.

AVITA Medical (NASDAQ:RCEL) had its target price cut by D. Boral Capital from $25.00 to $22.00. The firm currently has a buy rating on the stock.

SpringWorks Therapeutics (NASDAQ:SWTX) had its outperform rating reiterated by analysts at Wedbush. The firm currently has a $81.00 target price on the stock.

Tripadvisor (NASDAQ:TRIP) had its neutral rating reiterated by analysts at DA Davidson. They currently have a $16.00 target price on the stock.